特发性肺纤维化药物治疗研究进展  

Updates in pharmacotherapy for idiopathic pulmonary fibrosis

作　　者：张明蕊 黄歆梅 曹孟淑[1] Zhang Mingrui;Huang Xinmei;Cao Mengshu(Department of Respiratory and Critical Care Medicine,Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine,Nanjing 210008,China;Department of Respiratory and Critical Care Medicine,Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China)

机构地区：[1]南京中医药大学鼓楼临床医学院呼吸与危重症医学科,南京210008 [2]南京大学医学院附属鼓楼医院呼吸与危重症医学科,南京210008

出　　处：《国际呼吸杂志》2023年第11期1357-1364,共8页International Journal of Respiration

基　　金：国家自然科学基金 (82070064)。

摘　　要：特发性肺纤维化(IPF)是一种病因和发病机制未明的慢性进展性纤维化肺疾病,到目前为止尚缺乏有效的治疗手段。过去几十年内已开展了多项临床试验,以探索IPF患者药物治疗的安全性和有效性。直到2014年,美国食品药品监督管理局批准两种抗纤维化药物(吡非尼酮和尼达尼布)用于治疗IPF,但这两种药物也仅仅可减缓IPF患者的肺功能下降和疾病进展,并不能逆转肺纤维化。目前针对IPF发病机制新靶点的多种抗纤维化药物正在进行临床前试验,如结缔组织生长因子、自分泌运动因子、溶血磷脂酸和整合素αvβ6等,疗效仍需进一步研究。本综述总结近年来有关IPF药物治疗的研究进展,为新靶点药物的研发提供思路和依据。Idiopathic pulmonary fibrosis(IPF)is a chronic and progressive fibrotic lung disease with unclear etiology and pathogenesis.Currently,there is no effective treatment.In the past few decades,multiple clinical trials have been conducted to determine the safety and efficacy of pharmacological treatments for IPF patients.So far,only two drugs,pirfenidone and nintedanib,have been proven to effectively slow down the functional decline and disease progression of IPF,which were approved by the U.S.Food and Drug Administration(FDA)in 2014.In addition,the specific therapeutic effects and mechanisms of a series of anti-fibrotic drugs targeting the pathogenesis of IPF,including connective tissue growth factor,autotaxin,lysophosphatidic acids,and integrinαvβ6,require further investigation.This review summarizes the advances of pharmacological therapy for IPF and provides ideas and basis for the research and development of novel targeted drugs.

关 键 词：特发性肺纤维化 药物疗法 临床试验 

分 类 号：R563[医药卫生—呼吸系统]